Andreas Hartkopf
Overview
Explore the profile of Andreas Hartkopf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fasching P, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39998850
Backgound: The GeparOLA study evaluated paclitaxel(P) plus olaparib(O) in neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer (eBC) with homologous recombination deficiency (HRD). HRD was defined by high...
2.
Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401360.
PMID: 39883887
Purpose: To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for early breast cancer...
3.
Tauber N, Hilmer L, Dannehl D, Fick F, Hemptenmacher F, Krawczyk N, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796772
Background/objectives: This single-center analysis evaluated the number of potential candidates for endocrine-based oral maintenance therapy in a real-world setting, focusing on three therapeutic agents, namely, olaparib, abemaciclib, and ribociclib, for...
4.
Englisch J, Englisch A, Dannehl D, Eissler K, Tegeler C, Matovina S, et al.
Arch Gynecol Obstet
. 2024 Oct;
311(2):437-442.
PMID: 39466403
Purpose: Breast cancer is a primary cause of cancer-related death among women worldwide. Neoadjuvant chemotherapy (NACT) is a cornerstone treatment for locally advanced, non-metastatic breast cancer. Achieving pathological complete response...
5.
Krell J, Shaw D, McGrane J, Hartkopf A, Herrero A, Yeoh C, et al.
Future Oncol
. 2024 Oct;
20(40):3409-3419.
PMID: 39445504
The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced...
6.
Ebner F, Hartkopf A, Veselinovic K, Schochter F, Janni W, Lukac S, et al.
Cureus
. 2024 Sep;
16(8):e67458.
PMID: 39310414
Background The preparation of multidisciplinary team (MDT) meetings can be time-consuming. In addition to the clinical data being available digitally in subsystems, the preparation of more complex cases requires literature...
7.
Schaffler H, Jakob D, Huesmann S, Pfister K, Veselinovic K, Schochter F, et al.
Geburtshilfe Frauenheilkd
. 2024 Sep;
84(9):855-865.
PMID: 39229630
Introduction: The third-generation antibody-drug conjugates (ADC), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), recently obtained approval for metastatic breast cancer treatment across various subtypes and therapeutic contexts. Materials And Methods:...
8.
Thill M, Janni W, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, et al.
Breast Care (Basel)
. 2024 Jun;
19(3):183-191.
PMID: 38894953
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2024 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally...
9.
Luftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, et al.
Int J Cancer
. 2024 Mar;
155(1):128-138.
PMID: 38447007
BRAWO, a real-world study, assessed the efficacy, quality of life (QoL) and safety of EVE + EXE in postmenopausal women with HR+/HER2- advanced breast cancer (ABC) in routine clinical practice....
10.
Fehm T, Mueller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, et al.
Clin Chem
. 2024 Jan;
70(1):307-318.
PMID: 38175595
Background: The phenotypes of tumor cells change during disease progression, but invasive rebiopsies of metastatic lesions are not always feasible. Here we aimed to determine whether initially HER2-negative metastatic breast...